Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

This pop-up space for 2019 Novel Coronavirus (2019-nCoV) supports evidence generation by pooling protocols, tools, guidance, templates, and research standards generated by researchers and networks working on the response to this outbreak. Findings from previous outbreaks, largely obtained during MERS and SARS outbreaks, are also available. We aim to make research faster and easier, and to enable standardised, quality data to be collected and prepared for sharing.

Visit the Coronavirus outbreak knowledge hub

New Novel Coronavirus Resource: standardised case report forms and database, an international resource to facilitate the collection of multi-site standardised clinical data on patients hospitalised with suspected or confirmed infection with 2019-nCoV.

Many groups associated with ERGO are proud to be working on the novel coronavirus outbreak. Just a few of their activities are highlighted below;

A case record form (CRF) designed to enable the collection of standardised clinical data has been made available by the International Severe Acute Respiratory and Emerging Infection Consortium (ISARIC). ISARIC is a global federation of clinical research networks, providing a proficient, coordinated, and agile research response to outbreak-prone infectious diseases. ISARIC’s purpose is to prevent illness and deaths from infectious diseases outbreaks. 

ERGO is also part of the Platform for European Preparedness Against (Re-)emerging Epidemics (PREPARE) consortium, an EU funded network for harmonized large-scale clinical research studies of infectious diseases. PREPARE have circulated the standardised collection tool for nCoV among the Multi-centre  EuRopean study of MAjor Infectious Disease Syndromes (MERMAIDS) clinical network which includes more than 50 hospitals and primary care clinics in 12 European countries.

Similar stories

Attention and memory deficits persist for months after recovery from mild Covid

Researchers from Oxford’s Department of Experimental Psychology and Nuffield Department of Clinical Neurosciences have shown that people who have had Covid but don’t complain of long Covid symptoms in daily life nevertheless can show degraded attention and memory for up to 6-9 months.

Dramatic fall in hospital admissions for child infections since start of Covid-19 pandemic

Since the onset of the Covid-19 pandemic, there have been dramatic reductions in hospital admissions for common and severe childhood infections in England, most likely due to social distancing measures, school and workplace closures, and travel restrictions, finds a study published by The BMJ today.

Oxford team publish blueprint for making millions of doses of a new vaccine within 100 days

The University of Oxford’s vaccine manufacturing research team has today published a pre-print paper demonstrating the feasibility of a step change in the speed and volume of production of adenovirus-vectored vaccines against new virus variants or other future pandemics.

Research finds drug may benefit some patients hospitalised with COVID-19 pneumonia

A proof-of-concept trial involving Oxford researchers has identified a drug that may benefit some patients hospitalised with COVID-19 pneumonia.

Many Long COVID patients continue to experience symptoms one year after hospital discharge

People who were hospitalised with COVID-19 and continued to experience symptoms five months later, show limited further recovery one year after hospital discharge according to the latest results of a major national study.

Vaccines shown to induce lower levels of neutralising antibodies against Omicron coronavirus variant

Researchers from the University of Oxford have analysed the impact of the Omicron COVID-19 variant of concern on one of the immune responses generated by vaccination.